Expanding the Presence of the ALZpath Blood Test in Alzheimer Disease Research: Mike Banville

WATCH TIME: 4 minutes | Captions are auto-generated and may contain errors.

"We see the blood tests as an integral piece to really be able to diagnose people at large scale. For us, being at these events and having our tests involved in both academic and commercial studies is really important to keep moving us, the whole industry forward."

At the recently concluded 2025 Alzheimer’s Association International Conference, held July 27-30, in Toronto, Canada, ALZpath, a clinical stage pharmaceutical company, showcased data featuring its pTau217 antibody, a blood-based test for Alzheimer disease (AD), in 7 presentations and 30 posters. Overall, the findings reinforced the reliability of ALZpath’s proprietary pTau217 antibody in blood-based assays for early AD detection. Since 2023, the antibody has appeared in 90 publications, including 60 original research papers, generating over 34,500 individual data points, and has been highlighted in 157 posters and presentations at international scientific conferences.¹

Prior research has demonstrated the global reach of the ALZpath pTau217 antibody, spanning 18 countries including the United States, Canada, China, Italy, Spain, South Korea, and Sweden. Most studies involved cohorts larger than 100 participants, with 42% including ethnically and demographically diverse populations. Notably, 8 head-to-head comparison studies have assessed ALZpath’s antibody against other pTau217 antibodies and biomarkers, which further validated its reliability and clinical relevance for indentifying AD.

The ALZpath’s antibody was also used in the large-scale HUNT study, which analyzed 11,486 samples, including nearly 9,000 individuals over age 70, to assess AD-related brain changes. At AAIC 2025, Mike Banville, chief executive officer and president at ALZpath, discussed the growing adoption of ALZpath’s blood test in AD research. He underscored the test’s high accuracy, adaptability to multiple platforms, and its growing acceptance as a standard in both research and clinical settings. In addition, Banville also emphasized its potential in enabling earlier detection of the disease, which could improve treatment outcomes, and stressed the importance of global collaboration.

Click here for more coverage of AAIC 2025.

REFERENCES
1. Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment. News Release. ALZpath. Published July 28, 2025. Accessed August 15, 2025. https://alzpath.bio/global-momentum-and-validation-grows-at-aaic-for-alzpath-proprietary-ptau217-antibody-use-in-alzheimers-disease-research-diagnosis-and-treatment/